WebNitto BioPharma, Inc. is a clinical stage biopharmaceutical company located in San Diego focused on the discovery and development of novel RNA-based therapeutics for … WebAug 4, 2024 · (REMAP-CAP, ACTIV-4a, and ATTACC ClinicalTrials.gov numbers, NCT02735707, NCT04505774, NCT04359277, and NCT04372589.) abstract ... therapeutic-dose anticoagulation in patients with
Therapeutic Management of Hospitalized Adults With COVID-19
WebJul 4, 2024 · Latest: Results from the REMAP-CAP trial show that among critically ill patients with COVID-19 randomised to receive 1 or more therapeutic interventions, treatment with an IL-6 receptor antagonist had a greater than 99.9% probability of improved 180-day mortality compared with patients randomised to the control, and treatment with an antiplatelet had … WebThe BEAT CF PEx cohort will report clinical, treatment, and outcome data for PEx among people with CF and is intended to serve as a core (master) protocol for future nested, … kms office soft98
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients ...
WebNov 1, 2024 · Trial recommended to: REMAP-CAP. Date: 12 February 2024. Why it was recommended. Infliximab is widely used to treat inflammatory diseases such as arthritis. … WebAug 8, 2024 · The multiplatform ATTACC/ACTIV-4a/REMAP-CAP trial reported more organ support-free days for patients in the therapeutic heparin arm than in the usual care arm, but there was no difference between the arms in mortality or length of hospitalization. 12 The RAPID trial compared a therapeutic dose of heparin to a prophylactic dose in hospitalized … WebREMAP-CAP is a global network of leading experts, institutions and research networks. With over 300 participating sites worldwide, REMAP-CAP is a truly global trial. We have … kms office online